Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Immunoblastic Lymphadenopathy × Capecitabine × Clear all
NCT01158274 2014-11-07

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
BreastDermatologicGastrointestinalLymphoidOther hematologic neoplasm

Breast Neoplasms, Burkitt Lymphoma, Colonic Neoplasms, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Rectal Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma